IJID Regions,
Journal Year:
2024,
Volume and Issue:
14, P. 100505 - 100505
Published: Dec. 10, 2024
This
study
describes
the
clinical
and
paraclinical
features,
antibiotic
resistance
levels,
treatment
outcomes
of
Klebsiella
pneumoniae
septicemia
acquired
in
Vietnamese
community.
A
cross-sectional
descriptive
was
conducted
on
102
patients
with
community-acquired
sepsis
caused
by
K.
from
July
2018
to
2023.
pneumoniae-induced
community
had
a
septic
shock
rate
13.7%
death
10.8%.
Organ
dysfunction
were
higher
than
without
shock.
The
procalcitonin,
creatinine,
platelet
indexes
increased
more
group.
strains
resistant
cephalosporins
quinolones
(8-10%)
ampicillin
(87%).
Late
hospitalization
raises
risk
mortality
∼3.5
times,
combination
therapy
two
kinds
antibiotics
increases
∼1.8
times.
rates
9.1%
63.6%
after
4-6
2-3
weeks
therapy,
respectively.
Of
11
who
died,
90.9%
died
shock,
whereas
sepsis.
resulted
10.8%
died.
There
87%
ampicillin.
late
associated
death.
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Jan. 9, 2024
Abstract
Objective
To
investigate
the
characteristics
and
drug
resistance
patterns
of
Klebsiella
pneumoniae
(KPN)
infection
among
children
admitted
to
pediatric
intensive
care
unit
(PICU).
Methods
KPN
strains
obtained
from
17
domestic
PICUs
between
January
1,
2016,
December
31,
2022,
were
collected
for
analysis.
The
overall
condition
assessed
utilizing
WHO-NET
software.
Results
A
total
26613
identified,
2591
(9.7%)
isolated.
Among
which,
carbapenem-resistant
constituted
32.3%.
primary
sites
detection
respiratory
tract
(71.1%),
blood
(8.6%),
urinary
(7.1%).
KPN’s
penicillin
drugs
exceeded
90%.
rate
amoxicillin-clavulanic
acid
declined
70–48%,
whereas
it
remained
relatively
stable
at
approximately
31–33%
piperacillin-tazobactam.
rates
cephalosporins
50%.
cefoperazone-sulbactam
decreased
51.7%
in
2018
12.2%
2021
before
increasing
25.7%
2022.
ceftolozane-tazobactam
preceding
3
years
ranged
9.1–20.8%.
imipenem
meropenem
have
gradually
33.8%
40.2%
respectively,
ertapenem
has
increased
14.8–35.2%.
41.6–25.7%
levofloxacin,
while
considerably
high
63.8%
44.6%
moxifloxacin
ciprofloxacin,
respectively.
amikacin
29.1–9.1%.
exhibited
greatest
vulnerability
polymyxin
B,
tigecycline,
E,
with
0.9%,
2.2%
3.1%,
correspondingly.
Cross-resistance
analysis
revealed
that
no
strain
was
resistant
both
B
meropenem.
However,
varying
degrees
co-resistance
observed
tigecycline
(2%),
(16%),
(27%),
colistin
(37%)
levofloxacin
(41%),
Conclusion
clinical
isolation
significantly
elevated
PICU.
Additionally,
there
a
substantial
rise
over
span
7
years.
Consequently,
is
imperative
emphasize
prudent
utilization
antibiotics
patients,
implement
efficient
control
measures,
employ
suitable
combinations
effectively
tackle
this
urgent
matter.
